Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic …
R Motta-Guerrero, A Leon Garrido-Lecca… - Frontiers in …, 2024 - frontiersin.org
Background The EGFR gene encodes a protein that stimulates molecular pathways that
allow the growth and development of the tumor microenvironment. The current preferred …
allow the growth and development of the tumor microenvironment. The current preferred …
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
M Hu, C Zhong, J Wang, JQ Chen, T Zhou - Frontiers in Immunology, 2024 - frontiersin.org
Recently, targeted therapy and immunotherapy have emerged as effective treatment options
for non-small cell lung cancer (NSCLC). This progress has been facilitated by the rapid …
for non-small cell lung cancer (NSCLC). This progress has been facilitated by the rapid …
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer
H Bai, Y Zhou, W Liu, W Xu, L Cheng, Y Huo, H Ji… - Heliyon, 2024 - cell.com
Introduction The genetic heterogeneity of non-small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) mutations may affect clinical responses and …
epidermal growth factor receptor (EGFR) mutations may affect clinical responses and …
Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
J Ding, X Ding, J Zeng, X Liu - Frontiers in Pharmacology, 2024 - frontiersin.org
The third-generation EGFR-TKIs, such as osimertinib, aumolertinib, and furmonertinib, have
been recommended as the preferred treatment for EGFR-mutant advanced non-small cell …
been recommended as the preferred treatment for EGFR-mutant advanced non-small cell …